title: Vaccines against human papillomavirus infections: protection against cancer, genital warts or both?
abstract: Since 2006, three vaccines against infections and disease caused by human papillomavirus (HPV) became available in Europe-in 2006 a quadrivalent HPV 6/11/16/18 vaccine, in 2007 a bivalent HPV 16/18 vaccine and in 2015 a nonavalent HPV 6/11/16/18/31/33/45/52/58 vaccine. HPV 16 and 18 are the most oncogenic HPV strains, causing about 70% of cervical and other HPV-related cancers, HPV 6 and 11 cause 85% of all genital warts. The additional types of the polyvalent vaccine account for about 20% of invasive cervical cancer and >35% of pre-cancer. The potential differences between these vaccines caused some debate. All three vaccines give a robust and long-lasting protection against the strains in the various vaccines. The promise of cross-protection against other types (i.e. HPV 31/33/45) and hence a broader cancer protection was not fulfilled because these observations were confounded by the vaccine efficacy against the vaccine types. Furthermore, cross-protection was not consistent over various studies, not durable and not consistently seen in the real world experience. The protection against disease caused by oncogenic HPV strains was not compromised by the protection against low-risk types causing genital warts. The most effective cancer protection to date can be expected by the nonavalent vaccine, data indicate a 97% efficacy against cervical and vulvovaginal pre-cancer caused by these nine HPV types.
authors.affiliation: Department of Gynaecology and Obstetrics, Comprehensive Cancer Centre, Medical University of Vienna, Austria. Electronic address: elmar.joura@meduniwien.ac.at.
authors.forename: E A
authors.initials: EA
authors.lastname: Joura
authors.affiliation: Department of Gynaecology and Obstetrics, Comprehensive Cancer Centre, Medical University of Vienna, Austria.
authors.forename: S
authors.initials: S
authors.lastname: Pils
mesh_terms: D003218:Condylomata Acuminata / Q000517:prevention & control*; D005260:Female; D006801:Humans; D027383:Papillomaviridae / Q000276:immunology*; D053918:Papillomavirus Vaccines / Q000276:immunology*; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control / Q000821:virology*; D014846:Vulvar Neoplasms / Q000517:prevention & control / Q000821:virology*
chemical_list: D053918:Papillomavirus Vaccines
keywords: Cervical cancer; Genital warts; Human papillomavirus; Vaccine; Vulvar cancer